Humacyte Inc
HUMA
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
107.8% downsideOvervalued by 107.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.13 Billion |
|---|---|
| Enterprise Value | $1.15 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.26 |
| Beta | 2.31 |
| Outstanding Shares | 197,846,786 |
Return
| Return on Equity | -688.93% |
|---|---|
| Return on Assets | -72.43% |
| Return on Invested Capital | -96.73% |
Valuation & Multiples
| P/E Ratio | -2.64 |
|---|---|
| PEG | 1.82 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 569.21 |
| Enterprise Value to EBIT | -12.57 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 5.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4201▼ 15.41% |
|---|---|
| Total Calls | 1,263,000▲ 78.01% |
| Total Puts | 530,600▲ 30.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.31%▲ 2.37% |
|---|---|
| Total Invested | $35.88M▼ 32.48% |
| Investors Holding | 164▲ 12.00% |
ESG Score
No data
About Alpha Healthcare Acquisition Corp.
CEO: Mr. Rajiv Sarman Shukla Alpha Healthcare Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in New York, New York.
Relevant Senate Committees
This committee provides essential analysis and scoring for tax legislation, directly shaping the fiscal environment, corporate tax structures, and capital investment decisions that significantly impact financial services and M&A.
This powerful committee controls taxation, which directly influences corporate valuations, capital gains, and investment incentives, all fundamental to the financial services sector and the attractiveness of SPACs.
This committee directly regulates the financial system, including the SEC, which has primary oversight over SPACs (blank check companies) regarding their formation, IPOs, and financial disclosures.